MDSCs and TAMs suppress the anti-tumor cellular responses, promoting an epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)-driven upregulation of programmed death-ligand 1 (PDL1) [12]. The gene discussed is EGFR; the disease is neoplasm.